Pulmonary Hypertension as a Fatal Complication of Extrahepatic Portal Hypertension

1993 ◽  
Vol 3 (06) ◽  
pp. 373-375 ◽  
Author(s):  
K. Tokiwa ◽  
N. Iwai ◽  
K. Nakamura ◽  
I. Shiraishi ◽  
S. Hayashi ◽  
...  
Hepatology ◽  
2007 ◽  
Vol 3 (4) ◽  
pp. 588-592 ◽  
Author(s):  
Mark D. Cohen ◽  
Lewis J. Rubin ◽  
Wayne E. Taylor ◽  
Jennifer A. Cuthbert

ESC CardioMed ◽  
2018 ◽  
pp. 2506-2507
Author(s):  
John Coghlan

Screening programmes for pulmonary hypertension are justifiable in some circumstances but not others. The inherent inaccuracies of the diagnostic tools and the low prevalence of pulmonary hypertension renders screening programmes ineffective unless the population evaluated with the primary screening tool (echocardiography) can be enriched. At the recent World Symposium of Pulmonary Hypertension screening programmes were recommended in asymptomatic systemic sclerosis, BMPR2 mutation carriers, patients with portal hypertension, and some groups with HIV, hereditary telangiectasis(HHT) or mutation carriers for HHT and congenital heart disease.


2017 ◽  
Vol 83 (6) ◽  
pp. 208-209
Author(s):  
Neal Cooper ◽  
Jason D. Sciarretta ◽  
Ayolola Onayemi ◽  
John Davis

1972 ◽  
Vol 123 (1) ◽  
pp. 35-42 ◽  
Author(s):  
Jeremiah G. Turcotte ◽  
Charles G. Child

1999 ◽  
Vol 23 (6) ◽  
pp. 377-385 ◽  
Author(s):  
Manpreet Singh Gulati ◽  
Shashi Bala Paul ◽  
Narendra Kumar Arora ◽  
Manorama Berry

Sign in / Sign up

Export Citation Format

Share Document